Figure 6.

Knock down of PIP4K2B enhances EMT in response to TGFβ treatment. A. control (pLKO1) and PIP4K2B knockdown MCF10A cells were treated for 72 hours with TGFβ (10 ng/ml) as indicated . Cell Lysates were blotted with the indicated antibodies. B, RNA was extracted from a similar panel of cells described in A and the mRNA for epithelial (CDH1) or mesenchymal (VIM, FN1) markers or transcription factors that control EMT switching (SNAI1 and SNAI2) were measured using qRT-PCR. Relative mRNA expression was normalised against control cells. C. Expression data for PIP4K2B and CDH1 were downloaded from the Bittner et al array (336 samples) and the Curtis et al (2136 samples) breast cancer studies. The data were sorted for PIP4K2B expression and the CDH1 levels were determined in the bottom (Low) and top (High) 10% of PIP4K2B expressors. Statistical significance was determined using Students t-test and the probabilities are represented on the graphs as ** P <0.01, *** P <0.001.